DigiPath Licenses Olympus Digital Pathology Patents
HENDERSON, Nev. and CENTER VALLEY, Pa., USA, August 17, 2011 – DigiPath, Inc®, a provider of affordable, innovative and reliable digital pathology solutions, and Olympus America Inc., a precision technology leader designing and delivering innovative solutions in life science imaging and other product areas, have entered into a nonexclusive worldwide agreement allowing DigiPath and its OEM partners to access an extensive portfolio of Olympus patents in the field of virtual microscopy and digital pathology.
The patents involved in the licensing agreement cover methods, software and technology for creating, storing and delivering virtual microscopy images.
Virtual microscope slides enable professionals to review biopsies and other pathology images without handling traditional glass slides, and allow doctors to share high-resolution digital microscope images over telecommunication networks for second opinion consultation, tumor board review, and image arching functions.
“Licensing these patented technologies and approaches to innovative new companies like DigiPath is very important to us,” said Mr. Hidenao Tsuchiya, Vice President and General Manager of Olympus America Inc., Scientific Equipment Group. “Agreements like this help foster widespread digital pathology adoption where affordability and improving advanced patient care are vital.”
“DigiPath is delighted to work with Olympus,” said Eric Stoppenhagen, Chief Executive Officer for DigiPath. “Our clients and OEM partners can be assured their investments in digital pathology are stable and secure.”
About DigiPath, Inc.
DigiPath, Inc. provides the next generation of affordable, innovative, and reliable digital pathology solutions. DigiPath’s advisors bring over 60 years combined expertise in pioneering digital pathology, implementing over 500 installations at community pathology practices, hospitals, academic medical centers, reference laboratories, biopharma organizations, and life science research institutions worldwide.
About Olympus America Inc., Scientific Equipment Group
Olympus America Scientific Equipment Group provides innovative microscope imaging solutions for researchers, doctors, clinicians and educators. Olympus microscope systems offer unsurpassed optics, superior construction and system versatility to meet the ever-changing needs of microscopists, paving the way for future advances in life science.
Olympus is a precision technology leader, designing and delivering innovative solutions in its core business areas: Medical and Surgical Products, Life Science Imaging Systems, Industrial Measurement and Imaging Instruments and Cameras and Audio Products. Olympus works collaboratively with its customers and affiliates worldwide to leverage R&D investment in precision technology and manufacturing processes across diverse business lines. These include:
- Gastrointestinal endoscopes, accessories, and minimally invasive surgical products;
- Advanced research, clinical and educational microscopes and research and educational digital imaging systems;
- Industrial research, engineering, test, inspection and measuring instruments; and
- Digital cameras and voice recorders.
Olympus serves the healthcare field with integrated product solutions and financial, educational and consulting services that help customers to efficiently, reliably and more easily achieve exceptional results. Olympus develops breakthrough technologies with revolutionary product design and functionality for the consumer and professional photography markets, and also is the leader in gastrointestinal endoscopy and clinical and educational microscopes.?For more information, visit www.olympusamerica.com.
Olympus is a registered trademark of Olympus Corporation, Olympus America Inc., and/or their affiliates in the U.S. and/or other countries.
SAFE HARBOR STATEMENT
This Press Release may contain certain forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. DigiPath has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect DigiPath's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause DigiPath's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. DigiPath undertakes no obligation to update or provide advice in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.